Cited by 143Cancer-related Molecular PathwaysBRCA gene mutations in cancerOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 136 of the 172 references it cites were found in a registry or an index.

Mutational spectrum of p53 mutations in primary breast and ovarian tumors

Feki, Anis, Irminger-Finger, Irmgard·2004·Critical Reviews in Oncology/Hematology

DOI 10.1016/j.critrevonc.2004.07.002

Open this paper in CoChat — free account

Abstract

Breast and ovarian cancers, like other cancers, occur due to genetic damage. Research aimed to determine the specific genes involved in the development of breast and ovarian cancers will help to understand how normal breast and ovarian epithelial cells escape regulation of proliferation, apoptosis and senescence. It was determined that approximately 10% of ovarian cancers and 20-30% of breast cancers arise in women who have inherited mutations in cancer susceptibility genes such as BRCA1, BRCA2 and other DNA repair genes. The ability to perform genetic testing permits the identification of women at increased risk who can then be offered preventive strategies. The vast majority of ovarian and breast cancers are sporadic, presumably resulting from the accumulation of genetic damage over lifetime. Several genes involved in breast and ovarian carcinogenesis have been identified, most notably the p53 tumor suppressor. The recent availability of expression microarrays has facilitated the simultaneous screening of thousands of genes and this will extend further the understanding of molecular events involved in the dynamic development of ovarian and breast cancers. Then, all this knowledge could be translated into effective screening, surveillance, prevention, and treatment strategies in the future.

Integrity signals

Registry

Crossref · 10.1016/j.critrevonc.2004.07.002

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
Shao, Z. M., Wu, J., Shen, Z., & Nguyen, M. (2001) · PubMed · Cited by 64
Retracted
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
Cancer statistics, 1999
Landis, S., Murray, T., Bolden, S., & Wingo, P. A. (1999) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.1.8 · Cited by 3,068
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
Untitled work
Johnstone (2002) · doi:10.1016/s0092-8674(02)00625-6 · Cited by 1,876
p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.
Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., & Vogelstein, B. (1990) · PubMed · Cited by 1,065
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.
Fitzgibbons, P. L., Page, D., Weaver, D. L., Thor, A. D., Allred, D. C., Gm, C., Sg, R., O’Malley, F. P., Jf, S., Connolly, J., et al. (2000) · PubMed · doi:10.5858/2000-124-0966-pfibc · Cited by 1,016

Show all 172 references

Research works printed but not linked: 2

Takahashi, 2000, Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers, Int J Cancer, 89, 92, 10.1002/(SICI)1097-0215(20000120)89:1<92::AID-IJC15>3.0.CO;2-8 · DOI
HK. Annual report on the results of treatment in gynecological cancer. Vol. 18. Stokholm: FIGO; 1982.

Sorted by citations

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szállási, Z., Li, Q., Birkbak, N. J., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 982
Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y.-G., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 663
Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
Evading apoptosis in cancer
Fernald, K., & Kurokawa, M. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.07.006 · Cited by 606
Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment
Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
p53 and breast cancer, an update
Lacroix, M., Toillon, R., & Leclercq, G. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01172 · Cited by 390
Targeting the MDM2-p53 Interaction for Cancer Therapy
Shangary, S. K., & Wang, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5136 · Cited by 372
Targeting the MDM2–p53 Protein–Protein Interaction for New Cancer Therapy: Progress and Challenges
Wang, S., Zhao, Y., Aguilar, A., Bernard, D., & Yang, C.-Y. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026245 · Cited by 300
The rebel angel: mutant p53 as the driving oncogene in breast cancer
Walerych, D., Napoli, M., Collavin, L., & Sal, G. D. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs232 · Cited by 301
Targeting Protein–Protein Interactions for Therapeutic Intervention: A Challenge for the Future
Zinzalla, G., & Thurston, D. E. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.12 · Cited by 266
Modulation of Protein–Protein Interactions for the Development of Novel Therapeutics
Πέττα, Ι., Lievens, S., Libert, C., Tavernier, J. H., & Bosscher, K. D. (2015) · Molecular Therapy · doi:10.1038/mt.2015.214 · Cited by 248
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors
Holzer, P., Masuya, K., Furet, P., Kallen, J., Valat-Stachyra, T., Ferretti, S., Berghausen, J., Bouisset-Leonard, M., Buschmann, N., Pissot-Soldermann, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00810 · Cited by 203
New strategies for targeting the hypoxic tumour microenvironment in breast cancer
Ward, C., Langdon, S. P., Mullen, P., Harris, A. L., Harrison, D. J., Supuran, C. T., & Kunkler, I. H. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.08.004 · Cited by 185
An Illegitimate microRNA Target Site within the 3′ UTR of MDM4 Affects Ovarian Cancer Progression and Chemosensitivity
Wynendaele, J., Böhnke, A., Leucci, E., Nielsen, S. J., Lambertz, I., Hammer, S., Sbrzesny, N., Kubitza, D., Wolf, A. A., Gradhand, E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0527 · Cited by 171
Correlation between CpG methylation profiles and hormone receptor status in breast cancers
Feng, W., Shen, L., Wen, S., Rosen, D. G., Jelı́nek, J., Hu, X., Huan, S., Huang, M. L., Liu, J., Şahin, A. A., et al. (2007) · Breast Cancer Research · doi:10.1186/bcr1762 · Cited by 154
Developments of CRBN-based PROTACs as potential therapeutic agents
Wang, C., Zhang, Y., Wu, Y., & Xing, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113749 · Cited by 158
Perturbation of Rb, P53, and Brca1 or Brca2 Cooperate in Inducing Metastatic Serous Epithelial Ovarian Cancer
Szabova, L., Yin, C., Bupp, S., Guerin, T. M., Schlomer, J. J., Householder, D. B., Baran, M. L., Yi, M., Song, Y., Sun, W., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3834 · Cited by 122
Importance of TP53 codon 72 and intron 3 duplication 16bppolymorphisms in prediction of susceptibility on breast cancer
Costa, S., Pinto, D., Pereira, D., Rodrigues, H., Cameselle‐Teijeiro, J., Medeiros, R., & Schmitt, F. C. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-32 · Cited by 114
p53 stability is regulated by diverse deubiquitinating enzymes
Kwon, S., Saindane, M., & Baek, K. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.08.001 · Cited by 112
MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)
Khurana, A., & Shafer, D. A. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s172315 · Cited by 111
Small-molecule MDM2 inhibitors in clinical trials for cancer therapy
Wang, S., & Chen, F. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114334 · Cited by 104
Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer
Shangary, S., Ding, K., Qiu, S., Nikolovska-Coleska, Z., Bauer, J. A., Liu, M., Wang, G., Lu, Y., McEachern, D., Bernard, D., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0140 · Cited by 91
Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy
Xu, Y., Diao, L., Chen, Y., Liu, Y., Wang, C. Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt011 · Cited by 89
Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics
Zhao, Y., Bernard, D., & Wang, S. (2013) · Biodiscovery · doi:10.7750/biodiscovery.2013.8.4 · Cited by 91
UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas
Berlingieri, M. T., Pallante, P., Guida, M., Nappi, C., Masciullo, V., Scambia, G., Ferraro, A., Leone, V., Sboner, A., Barbareschi, M., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1210010 · Cited by 78
Development of selective small molecule MDM2 degraders based on nutlin
Wang, B., Wu, S., Liu, J., Yang, K., Xie, H., & Tang, W. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.046 · Cited by 77
An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
Mohammad, R. M., Wu, J., Azmi, A. S., Aboukameel, A., Sosin, A. M., Wu, S., Yang, D., Wang, S., & Al-Katib, A. M. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-115 · Cited by 80
Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors
Klajic, J., Fleischer, T., Dejeux, E., Edvardsen, H., Wärnberg, F., Bukholm, I. K., Lønning, P. E., Solvang, H. K., Børresen‐Dale, A., Tost, J., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-456 · Cited by 74
Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis
Wu, J., Vlastos, A., Pelte, M., Caligo, M. A., Bianco, A., Krause, K., Laurent, G. J., & Irminger‐Finger, I. (2005) · International Journal of Cancer · doi:10.1002/ijc.21428 · Cited by 74
Self-citation
Targeting the MDM2-p53 protein–protein interaction for new cancer therapeutics
Wang, S., Zhao, Y., Bernard, D., Aguilar, A., & Kumar, S. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_2 · Cited by 72
A Network of Substrates of the E3 Ubiquitin Ligases MDM2 and HUWE1 Control Apoptosis Independently of p53
Kurokawa, M., Kim, J., Geradts, J., Matsuura, K., Liu, L., Xu, R., Xia, W., Ribar, T. J., Henao, R., Dewhirst, M. W., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2003741 · Cited by 68
Both Germ Line and Somatic Genetics of the p53 Pathway Affect Ovarian Cancer Incidence and Survival
Bartel, F., Jung, J., Böhnke, A., Gradhand, E., Zeng, K., Thomssen, C., & Hauptmann, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1192 · Cited by 67
Concentration-dependent effects of genistein on global gene expression in MCF-7 breast cancer cells: an oligo microarray study
Lavigne, J. A., Takahashi, Y., Chandramouli, G. V. R., Liu, H., Perkins, S. N., Hursting, S. D., & Wang, T. T. Y. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9705-6 · Cited by 64
Ensemble-based virtual screening reveals dual-inhibitors for the p53–MDM2/MDMX interactions
Barakat, K., Mane, J. Y., Friesen, D. E., & Tuszyński, J. A. (2009) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2009.12.003 · Cited by 61
P53 mediated regulation of metallothionein transcription in breast cancer cells
Ostrakhovitch, E. A., Olsson, P., von Hofsten, J., & Cherian, M. G. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21381 · Cited by 62
Targeting mutant p53: a key player in breast cancer pathogenesis and beyond
Qayoom, H., Haq, B. U., Sofi, S., Jan, N., Jan, A., & Mir, M. A. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01863-9 · Cited by 68
Artemisinin Represses Telomerase Subunits and Induces Apoptosis in HPV‐39 Infected Human Cervical Cancer Cells
Mondal, A., & Chatterji, U. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25152 · Cited by 60
Taking Aim at the Undruggable
Coleman, N., & Rodon, J. A. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_325885 · Cited by 59
Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin‐3 in gastric cancer cells
Endo, S., Yamato, K., Hirai, S., Moriwaki, T., Fukuda, K., Suzuki, H., Abei, M., Nakagawa, I., & Hyodo, I. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01821.x · Cited by 61
Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin β4 and Akt signals
Lee, J.-G., Ahn, J., Kim, T. J., Lee, J. H., & Choi, J. (2015) · Scientific Reports · doi:10.1038/srep12642 · Cited by 60
Evidence that p53-Mediated Cell-Cycle-Arrest Inhibits Chemotherapeutic Treatment of Ovarian Carcinomas
Moreno, C. S., Matyunina, L. V., Dickerson, E. B., Schubert, N., Bowen, N. J., Logani, S., Benigno, B. B., & McDonald, J. F. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000441 · Cited by 57
Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers
Cybulski, C., Masojc, B., Oszutowska–Mazurek, D., Jaworowska, E., Grodzki, T., Waloszczyk, P., Serwatowski, P., Pankowski, J., Huzarski, T., Byrski, T., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn044 · Cited by 58
Computational strategy for intrinsically disordered protein ligand design leads to the discovery of p53 transactivation domain I binding compounds that activate the p53 pathway
Ruan, H., Chen, Y., Niu, X., Zhang, W., Liu, H., Chen, L., Xiong, R., Sun, Q., Jin, C., Liu, Y., et al. (2020) · Chemical Science · doi:10.1039/d0sc04670a · Cited by 57
Synthesis and Evaluation of Thiazolidinone–Pyrazole Conjugates as Anticancer and Antimicrobial Agents
Bhat, M., Boja Poojary, B., Kalal, B. S., Matada, G. S. P., Kabilan, S., Kumar, V., Shruthi, N., Anand, S. A. A., & Pai, V. R. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0191 · Cited by 55
Cell Survival and Cell Death at the Intersection of Autophagy and Apoptosis: Implications for Current and Future Cancer Therapeutics
Bata, N., & Cosford, N. D. P. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00130 · Cited by 60
Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia
Kamat, C. D., Green, D. E., Warnke, L. A., Thorpe, J. E., Ceriello, A., & Ihnat, M. A. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.08.017 · Cited by 53
MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis
Wan, Y., Wu, W., Yin, Z., Guan, P., & Zhou, B. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-208 · Cited by 52
A Review of the Ethnic Differences in Breast Cancer
Bowen, R., Stebbing, J., & Jones, L. (2006) · Pharmacogenomics · doi:10.2217/14622416.7.6.935 · Cited by 50
Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer
Neumeister, V. M., Sullivan, C. A. W., Lindner, R. M., Lezon-Geyda, K., Li, J., Závada, J., Martel, M., Glazer, P. M., Tuck, D. P., Rimm, D. L., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2232-0 · Cited by 48
Molecular predictors of response and outcome in ovarian cancer
Canevari, S., Gariboldi, M., Reid, J. F., Bongarzone, I., & Pierotti, M. A. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.03.003 · Cited by 44
miR-100 antagonism triggers apoptosis by inhibiting ubiquitination-mediated p53 degradation
Yang, G., Gong, Y., Wang, Q., Wang, L., & Zhang, X. (2016) · Oncogene · doi:10.1038/onc.2016.270 · Cited by 43
Benzyl Isothiocyanate potentiates p53 signaling and antitumor effects against breast cancer through activation of p53-LKB1 and p73-LKB1 axes
Xie, B., Nagalingam, A., Kuppusamy, P., Muniraj, N., Langford, P., Győrffy, B., Saxena, N. K., & Sharma, D. (2017) · Scientific Reports · doi:10.1038/srep40070 · Cited by 41
Improved Classification of Epithelial Ovarian Cancer
Steffensen, K. D., Waldstrøm, M., Grove, A., Lund, B., Pallisgaard, N., & Jakobsen, A. K. M. (2011) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e31822a0f6b · Cited by 40
The Sirtuin Inhibitor Tenovin-6 Upregulates Death Receptor 5 and Enhances Cytotoxic Effects of 5-Fluorouracil and Oxaliplatin in Colon Cancer Cells
Ueno, T., Endo, S., Saito, R., Hirose, M., Hirai, S., Suzuki, H., Yamato, K., & Hyodo, I. (2014) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504013x13854886566598 · Cited by 36
Human papillomavirus infection in B owen disease: Negative p53 expression, not p16 INK 4a overexpression, is correlated with human papillomavirus‐associated B owen disease
Murao, K., Yoshioka, R., & Kubo, Y. (2014) · The Journal of Dermatology · doi:10.1111/1346-8138.12613 · Cited by 35
Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation
Montano, X. (2009) · Oncogene · doi:10.1038/onc.2009.143 · Cited by 35
Therapeutic potential of stem cells expressing suicide genes that selectively target human breast cancer cells: Evidence that they exert tumoricidal effects via tumor tropism
YI, B.-R., CHOI, K. J., KIM, S. U., & CHOI, K.-C. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1523 · Cited by 32
Stochastic and Deterministic Models of Cellular p53 Regulation
Leenders, G. B., & Tuszyński, J. A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00064 · Cited by 28
Pathologic Aspects of Inflammatory Breast Cancer: Part 2. Biologic Insights Into Its Aggressive Phenotype
Gong, Y. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.11.014 · Cited by 30
Structural States of Hdm2 and HdmX: X‐ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes
Kallen, J. A., Izaac, A., Chau, S., Wirth, E., Schoepfer, J. G., Mah, R., Schlapbach, A., Stutz, S., Vaupel, A., Guagnano, V., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900201 · Cited by 30
Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment—In Vitro, In Vivo and Clinical Trials Literature Review
Szulc, A., & Woźniak, M. (2024) · Cancers · doi:10.3390/cancers16081483 · Cited by 32
Induction of p53 suppresses chronic myeloid leukemia
Peterson, L. F., Lo, M., Liu, Y., Giannola, D. M., Mitrikeska, E., Donato, N. J., Johnson, C. N., Wang, S., Mercer, J., & Talpaz, M. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1272682 · Cited by 24
Molecular Biology of Inflammatory Breast Cancer: Applications to Diagnosis, Prognosis, and Therapy
Wu, M., & Merajver, S. D. (2006) · Breast Disease · doi:10.3233/bd-2006-22104 · Cited by 24
Enhancing the Effects of Low Dose Doxorubicin Treatment by the Radiation in T47D and SKBR3 Breast Cancer Cells
Aghaee, F., Islamian, J. P., Baradaran, B., Mesbahi, A., Mohammadzadeh, M., & Jafarabadi, M. A. (2013) · Journal of Breast Cancer · doi:10.4048/jbc.2013.16.2.164 · Cited by 24
Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies
Bandaru, S., Ponnala, D., Lakkaraju, C., Bhukya, C. K., Shaheen, U., & Nayarisseri, A. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.9.3759 · Cited by 22
FOXA1 positively regulates gene expression by changing gene methylation status in human breast cancer MCF-7 cells.
Zheng, L., Qian, B., Tian, D., Tang, T., Wan, S., Wang, L., Zhu, L., & Geng, X. (2015) · Europe PMC (PubMed Central) · Cited by 22
Indolo‐pyrido‐isoquinolin based alkaloid inhibits growth, invasion and migration of breast cancer cells via activation of p53‐miR34a axis
Avtanski, D. B., Nagalingam, A., Tomaszewski, J. E., Risbood, P. A., Difilippantonio, M. J., Saxena, N. K., Malhotra, S. V., & Sharma, D. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.04.003 · Cited by 20
Genetic Determinants of Aggressive Breast Cancer
Ventura, A. C., & Merajver, S. D. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.59.060106.184830 · Cited by 20
S‐MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia
Liu, L., Fan, L., Cheng, F., Zou, Z., Yang, S., Zhang, L., Li, J., & Xu, W. (2012) · Cancer Science · doi:10.1111/cas.12008 · Cited by 20
Synthesis and Biological Evaluation of Novel Dispiro-Indolinones with Anticancer Activity
Ivanenkov, Y. A., Kukushkin, M. E., Beloglazkina, A. A., Shafikov, R. R., Barashkin, A. A., Ayginin, A. A., Serebryakova, M. S., Majouga, A. G., Skvortsov, D. A., Тафеенко, В. А., et al. (2023) · Molecules · doi:10.3390/molecules28031325 · Cited by 19
Biology and management of inflammatory breast cancer
Dawood, S. S. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.90 · Cited by 19
New targets for the treatment of follicular lymphoma
Tageja, N., Padheye, S., Dandawate, P. R., Al-Katib, A. M., & Mohammad, R. M. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-50 · Cited by 20
Structural determinants of benzodiazepinedione/peptide-based p53-HDM2 inhibitors using 3D-QSAR, docking and molecular dynamics
Wang, F., Li, Y., Ma, Z., Wang, X., & Wang, Y. (2011) · Journal of Molecular Modeling · doi:10.1007/s00894-011-1041-4 · Cited by 18
An observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomas
Touqan, N., Diggle, C. P., Verghese, E. T., Perry, S., Horgan, K. J., Merchant, W., Anwar, R., Markham, A. F., Carr, I., & Achuthan, R. (2013) · BMC Clinical Pathology · doi:10.1186/1472-6890-13-32 · Cited by 18
Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer
Montagut, A. M., Armengol, M., Gorjón-de-Pablo, G., Estrada‐Tejedor, R., Borrell, J. I., & Roué, G. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.02.007 · Cited by 17
Computational Investigation on the p53–MDM2 Interaction Using the Potential of Mean Force Study
Das, P., & Mattaparthi, V. S. K. (2020) · ACS Omega · doi:10.1021/acsomega.9b03372 · Cited by 18
p53 Expression in MCF7, T47D and MDA-MB 468 Breast Cancer Cell Lines Treated with Adriamycin Using RT-PCR and Immunocytochemistry
Kaabinejadian, S., Fouladdel, S., Ramezani, M., & Azizi, E. (2008) · Journal of Biological Sciences · doi:10.3923/jbs.2008.380.385 · Cited by 16
Discrimination of the Effects of Doxorubicin on Two Different Breast Cancer Cell Lines on Account of Multidrug Resistance and Apoptosis
Oncul, S., & Ercan, A. (2017) · Indian Journal of Pharmaceutical Sciences · doi:10.4172/pharmaceutical-sciences.1000268 · Cited by 16
MDMX in Cancer: A Partner of p53 and a p53-Independent Effector
Wu, L., Yan, Y., Huang, Q., & Zheng, D. (2024) · Biologics · doi:10.2147/btt.s436629 · Cited by 17
Design, Synthesis and Evaluation of 2,5-Diketopiperazines as Inhibitors of the MDM2-p53 Interaction
Pettersson, M., Quant, M., Min, J., Iconaru, L. I., Kriwacki, R. W., Waddell, M. B., Guy, R. K., Luthman, K., & Grøtli, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137867 · Cited by 15
Analysis and Design of Piezoelectric Braille Display
Smithmaitrie, P. (2009) · InTech eBooks · doi:10.5772/7391 · Cited by 12
USP19 Negatively Regulates p53 and Promotes Cervical Cancer Progression
Tyagi, A., Karapurkar, J. K., Colaco, J. C., Sarodaya, N., Antao, A. M., Kaushal, K., Haq, S., Chandrasekaran, A. P., Das, S., Singh, V., et al. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00814-y · Cited by 12
Immunohistochemical study of p53 and Ki67 in a group of patients with mammary carcinoma.
Pleşan, D. M., Georgescu, C. V., Pătrană, N., Pleşan, C., & Stoica, D. (2010) · PubMed · Cited by 11
A Case-Control Study of TP53 R72P Polymorphism in the Breast Cancer Patients of Ethnic Kashmiri Population
Syeed, N. (2010) · World Journal of Oncology · doi:10.4021/wjon261w · Cited by 10
MDM2 SNP309 and p53 codon 72 genetic polymorphisms and risk of AML: an Egyptian study.
El-Danasouri, N. M., Ragab, S. H., Rasheed, M. A., El-Saadany, Z. A., & El-Fattah, S. N. A. (2014) · PubMed · Cited by 11
Molecular and Cellular Biology
Stevenson, M. A., & Calderwood, S. K. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-24098-7.00002-2 · Cited by 11
Epistatic interaction of Arg72Pro TP53 and −710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival
Rodrigues, P., Furriol, J., Tormo, E., Ballester, S., Lluch, A. M., & Eroles, P. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1640-8 · Cited by 10
Molecular and Cellular Biology
Stevenson, M. A., & Calderwood, S. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1637-5.00002-x · Cited by 9
Modern approach of breast cancer diagnostics
TAMKOVICH, S. N., Voytsitskiy, V. E., & Laktionov, P. P. (2014) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20146002141 · Cited by 8
Synthetic approaches to constructing proteolysis targeting chimeras (PROTACs)
Bakulina, O., Sapegin, A., Bunev, A. S., & Krasavin, M. (2022) · Mendeleev Communications · doi:10.1016/j.mencom.2022.07.001 · Cited by 8
Ranking the Binding Energies of p53 Mutant Activators and Their ADMET Properties
Omar, S. I., & Tuszyński, J. A. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12480 · Cited by 8
Small‐molecule MDM2 inhibitor LQFM030‐induced apoptosis in p53‐null K562 chronic myeloid leukemia cells
Ribeiro, H. D. O., Cortez, A. P., de Ávila, R. I., da Silva, A. C. G., de Carvalho, F. S., Menegatti, R., Lião, L. M., & Valadares, M. C. (2020) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12540 · Cited by 8
Two different, mutually exclusively distributed, TP53 mutations in ovarian and peritoneal tumor tissues of a serous ovarian cancer patient: indicative for tumor origin?Preprint
Sukhbaatar, N., Bachmayr-Heyda, A., Auer, K., Aust, S., Deycmar, S., Horvat, R., & Pils, D. (2017) · Molecular Case Studies · doi:10.1101/mcs.a001461 · Cited by 8
Clinical utility of the imunohistochemical co-expression of p53 and MDM2 in thyroid follicular lesions
Martins, M. B., Batista, F. D. A., Marcello, M. A., Búfalo, N. E., Peres, K. C., Morari, E. C., Soares, F. A., Vassallo, J., & Ward, L. S. (2021) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2021.151766 · Cited by 7
PROGNOSTIC STATUS OF p53 PROTEIN ACCUMULATION IN CANINE MALIGNANT MAMMARY TUMOURS
Łopuszyński, W., Szczubiał, M., & Komsta, R. (2010) · Cited by 7
Molecular investigation of the dual inhibition mechanism for targeted P53 regulator MDM2/MDMX inhibitors
Zhao, X., Xiong, D., Luo, S., & Duan, L. (2022) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp01780f · Cited by 7
Radiation response and cell cycle regulation of p53 rescued malignant keratinocytes
Niemantsverdriet, M., Jongmans, W., & Backendorf, C. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.07.016 · Cited by 7

Authors: Feki, A., & Irminger-Finger, I.
Venue: Critical Reviews in Oncology/Hematology
Publisher: Elsevier BV
Published: 2004-11
Volume: 52
Issue: 2
Pages: 103-116
ISSN: 1040-8428 (ISSN-L)
DOI: 10.1016/j.critrevonc.2004.07.002
OpenAlex: W2071475683
Cited by: 139
References: 172
Citations by year: 2025: 5 · 2024: 3 · 2023: 3 · 2022: 5 · 2021: 7 · 2020: 5 · 2019: 4 · 2018: 4 · 2017: 9 · 2016: 4 · 2015: 13 · 2014: 7 · 2013: 12 · 2012: 9
FWCI: 0.57
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Critical Reviews in Oncology/Hematology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: TP53 mutation, mutation spectrum, breast cancer, ovarian cancer, tumor suppressor, BRCA1, BRCA2, hereditary cancer predisposition, sporadic cancer, carcinogenesis, DNA repair genes, genetic testing, cancer prevention
MeSH terms: Breast Neoplasms, Family Health, Female, Gene Frequency, Humans, Mutation, Ovarian Neoplasms, Prognosis, Tumor Suppressor Protein p53

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Mutational spectrum of p53 mutations in primary breast and ovarian tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks